Brand News

Horsham, Pa., December 31, 2009

Dudnyk Wins Inspire Pharmaceuticals Accounts

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) named Dudnyk, a multichannel, healthcare communications agency, as agency of record for two leading eyecare brands—AzaSite^® (azithromycin ophthalmic solution) and Elestat^® (epinastine HCl ophthalmic solution).

Rebranding and new professional promotion for the AzaSite brand will begin immediately. AzaSite is currently indicated for the treatment of bacterial conjunctivitis, but there is a significant opportunity for the future as the single entity ocular antibiotic market represents more than $400 million in annual sales in the US alone.

“It was Dudnyk’s bold approach that attracted us. We need to differentiate AzaSite in a crowded ophthalmic space; they have a knack for powerful positioning and creative that connects with our target audience of eye care professionals,” said Bill Volz, Vice President of Marketing, Inspire Pharmaceuticals.

Frank Powers, President at Dudnyk added, “Inspire is an innovative and progressive leader in ophthalmology. We couldn’t be more pleased to help them build a new brand image for AzaSite. Inspire is coming on strong, and we’re glad to be partnering with them.”

Inspire licensed the rights to commercialize AzaSite for ocular infections in the United States and Canada from InSite Vision in February 2007. The Food and Drug Administration (FDA) approved AzaSite for the treatment of bacterial conjunctivitis in April, 2007. AzaSite is a registered trademark owned by InSite.

About Dudnyk
Dudnyk isn’t the usual pharmaceutical ad agency. Independently owned. Multichannel. Specialty-focused. Strategic. Scientific. Creative. Powerful branded and unbranded communications for the pharmaceutical, biotech and device worlds. Reinventing the way medical marketing and professionals communicate since 1993. See dudnyk.com.